|Print Page Close Window|
Aptevo Therapeutics and the ADAPTIR™ (Modular Protein Technology) Platform: The Future of Immuno-oncology
Aptevo Therapeutics is a biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Our core technology is the ADAPTIR™ (modular protein technology) platform. We also have four commercial products that generate revenue in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immuno-oncology.
Stock Details Stock Summary | APVO | Nasdaq $2.28 - 0.15 (6.17%)
Updated October 16, 2017 4:00 p.m. ET
Aptevo Therapeutics Showcases New Mechanism of Action for Its ADAPTIR Platform at the Inflammation Research Society Meeting
© Aptevo BioTherapeutics, LLC.